Archive · 3 Jan 2026
Mankind Pharma's Transformation and Acquisition Challenges
Mankind Pharma has been going through big changes in the last year and a half.
They bought another company called BSV Pharma, which is doing well but hasn't made as much extra money as they hoped yet.
The company also reorganized its sales team, which slowed down their growth a bit.
They expect to grow faster soon and pay off the money they borrowed to buy BSV Pharma by 2028.
Right now, they're telling people to wait and see how these changes work out before buying their stock.
Mankind Pharma acquired BSV Pharma but is yet to see expected revenue synergies.
Internal reorganization has temporarily slowed down growth.
Domestic prescription segment grew 8-9% YoY in FY25, down from previous years.
Consumer health and export segments showed strong growth despite smaller contributions.
Company expects to clear acquisition debt by FY28, supporting future earnings growth.
- Who
- Mankind Pharma
- What
- Transformation and acquisition of BSV Pharma
- When
- Past one-and-a-half years, with debt expected to be cleared by FY28
- Where
- India, with exports to the US and Europe
- Why
- To achieve revenue synergies and high growth post-reorganization
- Acquisition
- BSV Pharma
- Acquisition Cost
- 27 times EV/EBITDA
- Expected Revenue Growth
- 18-20% in FY26
- Current Net Debt
- ₹4,791 crore (September 2025)
- Expected Debt Clearance
- FY28
- EBITDA Margins
- 25-26%
- Domestic Prescription Growth
- 8-9% YoY in FY25
- Consumer Health Growth
- 15% YoY in FY25